Table 2:

Patient outcomes on the CPT11–Avastin combination

Patient	Duration of Treatment	Time to progression	Overall survival	Karnofsky performance score at start of CPT-11–Avastin	Extra-cranial metastases	Rades score [9]	Predicted chance of 6-month survival (%)
1	21.5 months	21 months	26 months	60	No	7	10
2	10 months	11.5 months	14.75 months	60	Yes	4	10
3	6 months	6.75 months	7.5 months	50	Yes	4	10
4	4 months	Clinical deterioration at 5.75 months, without radiographic or CSF evidence of progression	6.5 months	40	Yes	4	10